logo-loader
viewFutura Medical PLC

Respected industry journal publishes data from phase II trial of Futura Medical’s MED2002 ED gel

The Journal of Sexual Medicine is a bit late to the party given that the headline results were announced back in September 2016 but Futura said it nonetheless shows the growing “level of scientific interest” in the gel

man with erectile dysfunction sitting on a bed
One of the key benefits to MED2002 is that it can be used by ED patients who can’t take Viagra or Cialis as it clashes with their existing medication

The positive data from the phase II trial of Futura Medical plc.’s (LON:FUM) MED2002 erectile dysfunction gel has been published in the well-respected and peer-reviewed Journal of Sexual Medicine.

The publication is a bit late to the party given that the headline results were announced back in September 2016 but Futura said it nonetheless shows the growing “level of scientific interest” in the gel.

Fast-acting ED treatment

MED2002 met its primary endpoint in the trials by showing a “statistically significant improvement” in erectile function in men with confirmed ED versus a placebo.

The JSM also included further data from the trial, including positive secondary outcome measures which show MED2002 improved orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction.

It also noted that 70% of participants in the study experienced onset of erection within ten minutes on average. Some of the current crop of pills available to ED sufferers can take longer than 20 minutes to kick in.

Publication underlines potential of MED2002

“The publication of the phase II clinical data in the leading, peer-reviewed scientific journal in sexual medicine underlines the robustness of our previously reported study and demonstrates the level of scientific interest in MED2002,” said chief executive James Barder.

“The article, in the Journal of Sexual Medicine, reinforces our belief that MED2002 has the potential to be the world's fastest-acting treatment for erectile dysfunction.”

First phase III trial on track for H1 2018

Barder added that pharmacokinetic study – which is being used to determine the doses used in the upcoming phase III trials – is coming along nicely having kicked off at the end of November.

He also confirmed that the first of the two of those phase III trials is on track to get underway in the first half of this year.

Quick facts: Futura Medical PLC

Price: 9.375 GBX

AIM:FUM
Market: AIM
Market Cap: £23.03 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Futura Medical kicks off work on Phase III trial for erectile dysfunction gel

James Barder, chief executive of Futura Medical PLC (LON:FUM), tells Proactive they've begun preparatory work on the first Phase III efficacy trial for MED2002 - their topical gel for erectile dysfunction (ED). The study will recruit approximately 1,000 patients with mild, moderate and...

on 27/4/18

2 min read